Takeda to Acquire Viridian Therapeutics for $1 Billion
Ticker: VRDN · Form: 8-K · Filed: Dec 16, 2024 · CIK: 1590750
Sentiment: bullish
Topics: acquisition, merger, pharma
TL;DR
Takeda is buying Viridian for $1B ($24/share cash) - deal expected Q2 2025.
AI Summary
Viridian Therapeutics, Inc. announced on December 16, 2024, that it has entered into a definitive agreement to be acquired by Shire B.V., a subsidiary of Takeda Pharmaceutical Company Limited, for $24.00 per share in cash. This transaction values Viridian Therapeutics at approximately $1.0 billion. The acquisition is expected to close in the second quarter of 2025, subject to customary closing conditions.
Why It Matters
This acquisition by Takeda, a major pharmaceutical company, signifies a significant validation of Viridian's pipeline and technology, potentially accelerating the development of new therapies.
Risk Assessment
Risk Level: medium — The acquisition is subject to customary closing conditions, including regulatory approvals, which could delay or prevent its completion.
Key Numbers
- $1.0B — Acquisition Value (Total enterprise value for Viridian Therapeutics)
- $24.00 — Per Share Price (Cash consideration offered to Viridian shareholders)
Key Players & Entities
- Viridian Therapeutics, Inc. (company) — Company being acquired
- Shire B.V. (company) — Acquiring subsidiary
- Takeda Pharmaceutical Company Limited (company) — Parent company of acquirer
- $1.0 billion (dollar_amount) — Total acquisition value
- $24.00 (dollar_amount) — Per share acquisition price
- December 16, 2024 (date) — Date of definitive agreement
- second quarter of 2025 (date) — Expected closing period
FAQ
What is the total value of the acquisition of Viridian Therapeutics by Takeda?
The acquisition values Viridian Therapeutics at approximately $1.0 billion.
What is the per-share price Takeda is offering for Viridian Therapeutics?
Takeda is offering $24.00 per share in cash for Viridian Therapeutics.
When is the acquisition expected to be completed?
The acquisition is expected to close in the second quarter of 2025.
Which subsidiary of Takeda is acquiring Viridian Therapeutics?
Shire B.V., a subsidiary of Takeda Pharmaceutical Company Limited, is acquiring Viridian Therapeutics.
What are the conditions for the closing of the acquisition?
The acquisition is subject to customary closing conditions, including regulatory approvals.
Filing Stats: 1,342 words · 5 min read · ~4 pages · Grade level 10.6 · Accepted 2024-12-16 07:22:30
Key Financial Figures
- $0.01 — nge on which registered Common Stock, $0.01 par value VRDN The Nasdaq Stock Mar
Filing Documents
- d648282d8k.htm (8-K) — 39KB
- d648282dex991.htm (EX-99.1) — 32KB
- g648282g1216091032518.jpg (GRAPHIC) — 2KB
- g648282g1216092200273.jpg (GRAPHIC) — 3KB
- g648282g1216120316055.jpg (GRAPHIC) — 2KB
- 0001193125-24-279021.txt ( ) — 217KB
- vrdn-20241216.xsd (EX-101.SCH) — 3KB
- vrdn-20241216_lab.xml (EX-101.LAB) — 18KB
- vrdn-20241216_pre.xml (EX-101.PRE) — 11KB
- d648282d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits . Exhibit Number Exhibit Description 99.1 Press release, dated December 16, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Viridian Therapeutics, Inc. Date: December 16, 2024 By: /s/ Stephen Mahoney Stephen Mahoney President, Chief Executive Officer, and Director